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doi:10.1016/j.jtcvs.2003.11.049686 The Journal of Thoracic and CardioObjective: Matrix metalloproteinases are endopeptidases that function in cell matrix
turnover. Abnormal matrix metalloproteinase activity has been implicated in the
formation of atherosclerotic abdominal aortic aneurysms. Recent studies suggest
that abnormal matrix metalloproteinase activity may also be associated with the
formation of atherosclerotic and nonatherosclerotic thoracic aortic aneurysms. Bi-
cuspid aortic valves are associated with an intrinsic aortic pathology that predis-
poses to formation of proximal thoracic aneurysms while tricuspid aortic valves are
not. The objective of this study was to compare the activities of matrix metallopro-
teinases and levels of their inhibitors in thoracic aneurysms of patients with bicuspid
and tricuspid aortic valves.
Methods: Endogenous and total activity of matrix metalloproteinase-2 and matrix
metalloproteinase-9 were measured in proximal nonatherosclerotic thoracic aortic
aneurysms of 16 patients with bicuspid aortic valves and 12 patients with tricuspid
aortic valves. Levels of tissue inhibitor metalloproteinase-1 and -2 were also
measured. Results were standardized to total protein (mg).
Results: Total matrix metalloproteinase-2 activity was greater in aneurysms asso-
ciated with bicuspid valves when compared with those from tricuspid valves (43 
11 ng/mg vs 14  2 ng/mg, P  .02). Total matrix metalloproteinase-9 activity was
also greater in aneurysms associated with bicuspid aortic valves (4.0  0.9 vs 1.5
 0.3, P  .02). There was no meaningful difference between groups in levels of
tissue inhibitor-1 and -2.
Conclusion: The increased activity of matrix metalloproteinases in the walls of
aneurysms associated with bicuspid aortic valves may partly explain the predilection
to aneurysm formation in these patients.
The proximal thoracic aorta of patients with bicuspid aortic valves ispredisposed to dilatation and aneurysm formation.1-3 Many investi-gators have shown that these patients have intrinsic abnormalities inthe structural integrity of their aortic walls.4-8 Abnormal elasticproperties within the ascending aorta have been documented byechocardiography in young patients with bicuspid aortic valves.4
Prominent histologic findings in patients with bicuspid valves include alterations in
the elastic lamellae within the media of the proximal thoracic aorta. Notably, there
is an increase in elastin fragmentation,5,7 which occurs even in the absence of
6aneurysmal disease.
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aneurysms and is thought to be a key factor in aneurysm
pathogenesis. Much recent attention has focused on matrix
metalloproteinases as a cause of this structural degeneration
leading to aneurysm formation.9 Matrix metalloproteinases
are endopeptidases that are synthesized and secreted by the
cellular components of the vessel wall and inflammatory
cells. Metalloproteinases normally function in extracellular
matrix turnover by degrading matrix proteins such as col-
lagen, elastin, and proteoglycans.10 The walls of abdominal
aortic aneurysms, however, are known to have an imbalance
in this normal turnover mechanism such that matrix metal-
loproteinase activity is significantly higher in the walls of
aneurysms than in controls.11,12 This is particularly true for
matrix metalloproteinase-9, which is released by tissue
macrophages associated with the inflammatory environment
of the atherosclerotic plaque.11,13 This imbalance favors
elastin fragmentation, which is thought to be the primary
event in aneurysm formation.14
Recent evidence suggests that an alteration in matrix
metalloproteinase activity also occurs in thoracic aortic an-
eurysms.15-17 A previous study found that matrix metallo-
proteinase-9 activity was elevated in thoracic aortic aneu-
rysms of atherosclerotic etiology when compared with those
of nonatherosclerotic etiology and age-matched controls.16
This current study sought to characterize the role of matrix
metalloproteinases and their inhibitors in patients with non-
atherosclerotic degenerative proximal thoracic aneurysms
associated with bicuspid aortic valves.
Materials and Methods
Patients
Samples of discarded aortic root and ascending aortic aneurysm
tissue, taken from the anterior wall of the aneurysm adjacent to the
sinotubular ridge, were collected from patients undergoing elective
aortic reconstruction for proximal nonatherosclerotic thoracic aor-
tic aneurysms at Fletcher Allen Health Care between December 1,
2000, and December 30, 2002. Patients with documented athero-
sclerotic changes within the aneurysm wall by either gross inspec-
tion or by histologic examination (hematoxylin and eosin staining)
were excluded. By doing this, we sought to eliminate patients in
whom the inflammatory infiltrate associated with an atheroscle-
rotic plaque could be a major component of aneurysm formation.
Atheroma contains an inflammatory infiltrate, including the tissue
macrophage, which synthesize and secrete matrix metalloprotein-
ase-9.18
Aortic specimens were collected from 28 patients with nonath-
erosclerotic, proximal thoracic aortic aneurysms. Sixteen patients
had an associated bicuspid aortic valve and 12 patients had a
tricuspid aortic valve. None of the patients had Marfan syndrome
or aortic dissection.
The medical record of each patient was reviewed and the
pertinent medical history was recorded. The study met with criteria
set forth by the Institutional Review Board of this institution.
The Journal of ThoraciTissue Handling and Preparation
The aortic tissue was immediately placed in a phosphate-buffered
saline solution at 4°C and transported to the laboratory where it
was snap-frozen in liquid nitrogen and stored at 80°C until the
time of preparation and analysis. Our operating room policy for-
bids the transport of liquid nitrogen within the operating room
facility. At the time of analysis, tissue samples (0.15-0.4 g wet
weight) were homogenized in 1 mL of 50 mmol/L Tris-HCl buffer
(1.5 mmol/L NaCl, 0.5 mmol/L CaCl2, 1 mol/L ZnCl2, and
0.01% [v/v] polyoxyethelene laurel ether [BRIJ 35; Biomedia
Corporation, Foster City, Calif]) at 4°C, pH 7.4, and placed on ice.
The homogenates were then spun at 8000 revolutions per minute
(rpm) for 5 minutes and the supernatants from each sample were
collected. The pellets were then resuspended in 1 mL 50 mmol/L
Tris and a second homogenization was performed, followed by
centrifugation at 8000 rpm for 5 minutes. The combined superna-
tants from each sample were spun at 10,000 rpm for 10 minutes
and the final supernatant was collected and used for analysis. Total
protein concentrations (mg/mL) were quantified in each final su-
pernatant sample using a protein assay (BIO-RAD, Hercules,
Calif).
The endogenous and total activity of matrix metalloprotein-
ase-2 and -9 was quantified in the supernatants by activity assays
(MMP-2 and MMP-9 Biotrak Activity Assay System, Amersham
Biosciences Corp, Piscataway, NJ). These activity assays are based
on an antibody-capture technique that sequesters both the active
and inactive forms of the metalloproteinase. Bound endogenously
active metalloproteinase activates a detection enzyme, which in
turn activates a detectable chromogenic substrate. Total metallo-
proteinase activity (endogenously active plus the activatable
proenzyme) is measured by the addition of -aminophenylmercu-
ric acetate, which artificially activates the inactive form of the
metalloproteinase. The term “endogenous activity,” therefore, re-
fers to extractable bioactive metalloproteinase, and the term “total
activity” refers to the detectable endogenous activity plus the
artificially activated proenzyme. Based on preliminary data show-
ing lower levels of endogenous metalloproteinase activity, we
utilized the longer incubation protocol to increase sensitivity of the
assay, as suggested by the manufacturer.
The levels of tissue inhibitor metalloproteinase-1 and -2
(TIMP-1 and -2) were quantified in the supernatants by enzyme-
linked immunosorbent assay (TIMP-1 and TIMP-2 Biotrak
ELISA, Amersham Biosciences Corp). The activity values and
inhibitor levels were standardized to total protein by dividing each
by the total protein concentration assayed from the final superna-
tant.
Statistical Analysis
Results are displayed as mean values standard error of the mean
(SEM). Differences in means between groups were tested using the
unpaired Student t test. Satterthwaite’s approximation was used
when there was evidence of unequal variance. Fisher exact test was
used to compare clinical variables between groups.
Results
By histologic examination all specimens showed some de-
gree of cystic medial degeneration with fragmentation of
elastic fibers. The presence of cystic medial necrosis was
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eroma. No important differences were seen between the
groups with regard to age, aneurysm size, gender, history of
any valvular dysfunction, smoking, associated coronary ar-
tery disease, hypertension, or use of beta-blockers, calcium
channel blockers, or angiotensin-converting enzyme inhib-
itors (Table 1). However, a trend was noted toward younger
age in the bicuspid group. The tricuspid group had a higher
incidence of aortic insufficiency when compared with the
bicuspid group (67% vs 25%, Fisher exact test, P  .05).
Quantitative activity analysis of aneurysmal tissues
showed that the endogenous activity of matrix metallopro-
teinase-2 was greater in the bicuspid group, but this did not
Figure 1. The endogenous activity of matrix metalloproteinase-2
in aneurysm walls of patients with bicuspid and tricuspid aortic
valves (mean values  SEM, standardized to total protein).
MMP-2, Matrix metalloproteinase-2.
Figure 2. The total activity of matrix metalloproteinase-2 in an-
eurysm walls of patients with bicuspid and tricuspid aortic
valves (mean values  SEM, standardized to total protein; *P 
.02, Student t test). MMP-2, Matrix metalloproteinase-2.reach statistical significance (0.84  0.24 ng/mg protein vs
688 The Journal of Thoracic and Cardiovascular Surgery ● Mar0.46  0.06 ng/mg protein; t test, P  .18; Figure 1). The
total matrix metalloproteinase-2 activity was also greater in
the walls of aneurysms associated with bicuspid aortic
valves compared with tricuspid valves (43  11 ng/mg
protein vs 14  2 ng/mg protein; t test, P  .02; Figure 2).
No meaningful difference was found in the endogenous
activity of matrix metalloproteinase-9 between the 2 groups
(bicuspid: 0.31  0.2 ng/mg protein vs tricuspid: 0.11 
0.06 ng/mg protein; t test, P  .20; Figure 3). Aneurysms
associated with bicuspid aortic valves, however, had greater
total matrix metalloproteinase-9 activity when compared
with aneurysms associated with tricuspid aortic valves (4.0
 0.9 ng/mg protein vs 1.5  0.35 ng/mg protein; t test, P
 .02; Figure 4).
No meaningful differences were noted in the levels of
tissue inhibitors-1 and -2 between groups (t test, P  .20).
Tissue inhibitor-1 levels were 156  26 ng/mg protein in
the bicuspid group and 172  35 ng/mg protein in the
tricuspid group. Levels of tissue inhibitor-2 were 22  5
ng/mg protein in the bicuspid group and 21  3 ng/mg
protein in the tricuspid group (Figure 5).
Discussion
This study lends support to recent preliminary findings by
others19 that link an intrinsic biochemical abnormality
within the walls of proximal thoracic aneurysms of patients
with bicuspid aortic valves to previously reported clinical
and histologic structural abnormalities. Specifically, the di-
minished distensibility, increased stiffness, dilatation, and
fragmentation of elastic components within the aortic wall
of patients with bicuspid aortic valves may be associated
with the increased expression of matrix-degrading pro-
teases.
Matrix degrading enzymes, metalloproteinase-2 and -9,
TABLE 1. Patient demographics
Bicuspid valve,
n  16 (%)
Tricuspid valve,
n  12 (%) P value
Age (mean, y) 54.7 6.2 63.9 10.1 .09
Size (mean, cm) 5.4 0.3 5.7 0.5 .23
Sex (male) 14 (88) 11 (92) 1.00
Hypertension 10 (63) 9 (75) .69
Aortic insufficiency 4 (25) 8 (67) .05
Aortic stenosis 8 (50) 2 (17) .11
Any valve dysfx. 12 (75) 10 (83) .67
Hyperlipidemia 6 (38) 3 (25) .69
Tobacco use 7 (44) 4 (33) .70
CAD 8 (50) 4 (33) .46
-blocker 9 (56) 5 (42) 1.00
Ca2 channel blocker 1 (6) 0 (0) 1.00
ACE inhibitor 5 (31) 7 (58) .25
Any valve dysfx. Any aortic valvular dysfunction, including both insuffi-
ciency and stenosis; CAD, coronary artery disease; -blocker, beta block-
er; ACE, angiotensin-converting enzyme.have been associated with the formation of abdominal aortic
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the most prominent protease associated with the formation
of abdominal aortic aneurysms because of its link to the
inflammatory infiltrate associated with these aneurysms.20
The vast majority of abdominal aortic aneurysms are ath-
erosclerotic in origin, and their walls contain atheroma
associated with an inflammatory cell infiltrate, including the
tissue macrophage. Tissue macrophages are the major
source of synthesis and secretion of matrix metalloprotein-
ase-9.9 In a previous study, the walls of thoracic aortic
aneurysms of atherosclerotic origin were found to contain
significantly higher matrix metalloproteinase-9 activity
when compared with nonatherosclerotic degenerative tho-
racic aneurysms and age-matched controls.16
The present study sought to quantitate the activity of
matrix metalloproteinases and levels of their inhibitors in
thoracic aortic aneurysms associated with bicuspid aortic
valves. Because aneurysms associated with bicuspid aortic
valves are degenerative in nature,6,7 they were compared
with degenerative aneurysms associated with tricuspid aor-
tic valves. Patients in both groups with documented athero-
sclerotic changes within the aortic wall were excluded from
the study to eliminate the contribution of the inflammatory
cell infiltrate. This should allow a more accurate analysis of
the contribution of the intrinsic cellular subtypes, such as
the smooth muscle cell and endothelial cell, to matrix met-
alloproteinase metabolism in these patients. The smooth
muscle cell is a major source of the synthesis and secretion
of metalloproteinase-2, TIMP-1, and TIMP-2 within the
aortic wall, although it also has the capability to synthesize
metalloproteinase-9.10
Because the proximal thoracic aortas of patients with
bicuspid valves have abnormal elastic properties, which are
Figure 3. The endogenous activity of matrix metalloproteinase-9
in aneurysm walls of patients with bicuspid and tricuspid aortic
valves (mean values  SEM, standardized to total protein).
MMP-9, Matrix metalloproteinase-9.present even before aneurysmal dilatation, it was hypothe-
The Journal of Thoracisized that aneurysms associated with bicuspid valves would
have an increased activity of the elastin-degrading metallo-
proteinases when compared with aneurysms from patients
with tricuspid aortic valves. There are 23 known matrix
metalloproteinases expressed in human tissue.10 Matrix
metalloproteinase-2 and -9 were chosen for analysis in this
study because of their known elastolytic properties21 and
because of their known association with the formation of
abdominal aortic aneurysms.
These data show that the potential for increased activity
of matrix metalloproteinase-2 and -9 are greater in the walls
of aortic aneurysms associated with bicuspid aortic valves
Figure 4. The total activity of matrix metalloproteinase-9 in an-
eurysm walls of patients with bicuspid and tricuspid aortic
valves (mean values  SEM, standardized to total protein; *P 
.02, Satterthwaite’s t test). MMP-9, Matrix metalloproteinase-9.
Figure 5. The levels of tissue inhibitor of matrix metalloprotein-
ase in aneurysm walls of patients with bicuspid and tricuspid
aortic valves (mean values  SEM, standardized to total protein).
TIMP-1, Tissue inhibitor of matrix metalloproteinase-1; TIMP-2,
tissue inhibitor of matrix metalloproteinase-2.when compared with aneurysms from patients with tricus-
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between groups in regard to the presence of the bioactive
species, there were significantly greater concentrations of
the potentially inducible proenzyme form of both matrix
metalloproteinase-2 and -9. This suggests that the previ-
ously documented abnormal elastic properties and the in-
creased risk for aneurysm formation in patients with bicus-
pid aortic valves may reflect the increased activity of these
matrix degrading proteins within the aortic wall.
This evidence, however, does not negate the role that
these proteases may play in the formation of proximal
thoracic aneurysms in patients with tricuspid valves. What it
may suggest, however, is that patients with bicuspid aortic
valves have a predisposition to abnormal matrix metallo-
proteinase metabolism and may be more susceptible to
aneurysmal dilatation when exposed to other known risk
factors. Several risk factors for aneurysmal dilatation, in-
cluding hypertension, are known to induce the expression of
matrix metalloproteinases.9,22
Investigations into the mechanisms causing structural
abnormalities in the aortas of patients with bicuspid aortic
valves have found an increased rate of smooth muscle cell
apoptosis, even in the absence of aneurysmal dilatation.8
Similar findings have been noted in abdominal aortic aneu-
rysms.23,24 Interestingly, several of the tissue inhibitors of
metalloproteinases, 4 of which have been identified in ver-
tebrates,10 have been shown to inhibit smooth muscle cell
apoptosis. Both tissue inhibitor-1 and -2 have antiapoptotic
properties.25,26 Overexpression of tissue inhibitor-1 in a rat
model of aortic aneurysm prevented degeneration and rup-
ture.27
This current study found no differences in the levels of
tissue inhibitor-1 and -2 in the walls of aneurysms from the
2 groups. Interestingly, the levels of tissue inhibitor-1 found
in this study were over twofold lower, and tissue inhibitor-2
was over fivefold lower, than values obtained from age-
matched aortas of patients undergoing coronary artery by-
pass grafting at this institution (unpublished data). There-
fore, the ratio of metalloproteinases to their inhibitors may
play an important role in aneurysm formation in both the
bicuspid and tricuspid groups and requires further study.9
Because we found no differences between groups relative to
the levels of tissue inhibitor, selective levels of tissue acti-
vators of the proenzyme forms may be more important in
aneurysm generation between the 2 groups; this also re-
quires further study.
A transition from a contractile to a synthetic phenotype
in the smooth muscle cells may be more important in
aneurysm formation than cellular loss or apoptosis. Smooth
muscle cells cultured from abdominal aortic aneurysm spec-
imens have been shown to produce significantly greater
levels of matrix metalloproteinase-2 and -9 when compared
28,29 15with controls. Lesaukaite and colleagues found in-
690 The Journal of Thoracic and Cardiovascular Surgery ● Marcreased concentrations of matrix metalloproteinase-1, -2,
and -9 in the walls of thoracic aortic aneurysms in the
absence of significant smooth muscle cell loss. They pro-
posed that mechanical forces, such as hypertension, could
cause changes in intracellular contacts between smooth
muscle cells, which may be responsible for this phenotypic
conversion.
Genotype abnormalities can directly cause thoracic aor-
tic aneurysms, as with the defect in the fibrillin-1 gene in
patients with Marfan syndrome. In a mouse model of
Marfan syndrome, a mutation in the gene encoding fibrillin
changed smooth muscle cells from a contractile to a syn-
thetic phenotype. This was associated with an increased
production of matrix metalloproteinase-9 within the aortic
wall and subsequent elastin fragmentation.30 Segura and
colleagues17 have documented an up-regulation of the syn-
thesis of matrix metalloproteinase-2 and -9 in Marfan pa-
tients with thoracic aortic aneurysms. Fedak and col-
leagues19 have suggested a link between fibrillin-1
deficiency and increased matrix metalloproteinase-2 activity
in the proximal aorta of patients with bicuspid aortic valves.
One could postulate that nonatherosclerotic degenerative
aneurysms of the proximal thoracic aorta may form after the
induction of a phenotypic change in the smooth muscle cell,
such as exposure to long-standing hypertension. Patients
with bicuspid aortic valves may have a greater predisposi-
tion to this change in phenotype by a preexisting genetic
defect. The timing and onset of these changes may be
earlier, and with greater severity, in the aortic wall associ-
ated with a bicuspid aortic valve, offering 1 explanation as
to why there are higher activities of matrix metalloprotein-
ase-2 and -9 in these patients. Recent work by the group at
Washington University in St Louis supports this hypothesis.
They documented differing patterns of gene expression in
the walls of aneurysms from patients with bicuspid aortic
valves when compared with those from patients with tricus-
pid aortic valves.31
Limitations
This study is purely observational in scope and was per-
formed with a limited number of patients and tissue sam-
ples. Tissue was obtained and analyzed at an isolated point
in time in a continuum of disease progression. As such, a
cause-and-effect relationship between metalloproteinase ex-
pression and aneurysmal dilatation cannot definitively be
concluded. In addition, these data cannot be interpreted as a
generalization that all patients with bicuspid aortic valves
have an intrinsic abnormality in matrix metalloproteinase
metabolism. The patients in this study were selected be-
cause they already had aneurysmal dilatation. Many indi-
viduals with bicuspid aortic valves do not develop aneurys-
mal dilatation, just as others never develop a clinical
problem with their structurally abnormal valve.
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tivity ex vivo. Bioactivity assays were not utilized. Also,
total metalloproteinase activity was measured after artificial
induction and does not represent the potential myriad of
constraints on activation or inhibition in vivo.
Finally, this study was not designed to correlate metal-
loproteinase activity and inhibitor levels with the grade or
degree of histological changes. Perhaps a stronger argument
for the association of increased metalloproteinase activity
with aneurysmal dilatation in patients with bicuspid valves
could be made if this study had sought to show a greater
degree of elastin fragmentation in these patients when com-
pared with the tricuspid group.
Conclusion
An increased expression of matrix metalloproteinase-2 and -9
activity exists in nonatherosclerotic proximal thoracic aortic
aneurysms of patients with bicuspid aortic valves when com-
pared with proximal thoracic aneurysms of patients with tri-
cuspid aortic valves. These alterations in 2 prominent extra-
cellular matrix proteases may help explain the structural and
histologic changes, mostly related to elastin metabolism, seen
in patients with bicuspid aortic valves. A genetic alteration in
matrix metalloproteinase metabolism may explain the suscep-
tibility and earlier onset of aortic pathology seen in some
patients with bicuspid aortic valves.
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